Overview
Headquarters
Great Lakes , Midwestern US
Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Juventas Therapeutics, Inc. operates as a clinical-stage biotechnology company. The Company discovers and develops biopharmaceutical therapies for regenerative medicine. Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
